NCT06021600: A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE1. Conditions: Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia